Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ...
Antibody-coupled drug ADCs are a hot frontier in cancer therapy, providing a targeted therapy approach that combines the specificity of monoclonal antibodies with the potency of cytotoxic agents.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
